Free Trial
LON:STX

Shield Therapeutics (STX) Share Price, News & Analysis

Shield Therapeutics logo
GBX 3.20 +0.32 (+11.11%)
As of 11:56 AM Eastern

About Shield Therapeutics Stock (LON:STX)

Key Stats

Today's Range
2.88
3.40
50-Day Range
2.28
3
52-Week Range
1.50
5.87
Volume
2.39 million shs
Average Volume
1.93 million shs
Market Capitalization
£31.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive STX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STX Stock News Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Shield Therapeutics awards CEO share options
Shield Thera Regulatory News
See More Headlines

STX Stock Analysis - Frequently Asked Questions

Shield Therapeutics' stock was trading at GBX 2.70 at the beginning of the year. Since then, STX shares have increased by 18.5% and is now trading at GBX 3.20.

Shield Therapeutics plc (LON:STX) issued its earnings results on Thursday, April, 24th. The company reported ($3.00) earnings per share (EPS) for the quarter. Shield Therapeutics had a negative trailing twelve-month return on equity of 470.50% and a negative net margin of 173.43%.

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), AstraZeneca (AZN), Model N (MODN), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS) and Cellectis (CLLS).

Company Calendar

Last Earnings
4/24/2025
Today
7/11/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Computer Hardware
Current Symbol
LON:STX
CIK
N/A
Fax
N/A
Employees
40,000
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (3.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
45.22
P/E Growth
N/A
Net Income
-£36.28 million
Net Margins
-173.43%
Pretax Margin
N/A
Return on Equity
-470.50%
Return on Assets
-47.85%

Debt

Debt-to-Equity Ratio
3,691.50
Current Ratio
1.05
Quick Ratio
2.16

Sales & Book Value

Annual Sales
£20.92 million
Price / Sales
1.51
Cash Flow
GBX 0.50 per share
Price / Cash Flow
6.36
Book Value
GBX 0.05 per share
Price / Book
58.48

Miscellaneous

Outstanding Shares
986,864,211
Free Float
N/A
Market Cap
£31.58 million
Optionable
Not Optionable
Beta
1.42
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (LON:STX) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners